Nationwide prevalence of lymph node metastases in Gleason score 3+3=6 prostate cancer

被引:25
|
作者
Liu, Jen-Jane [1 ]
Lichtensztajn, Daphne Y. [2 ]
Gomez, Scarlett Lin [2 ]
Sieh, Weiva [3 ]
Chung, Benjamin I. [1 ]
Cheng, Iona [2 ]
Brooks, James D. [1 ]
机构
[1] Stanford Univ, Sch Med, Dept Urol, Stanford, CA 94305 USA
[2] Canc Prevent Inst Calif, Fremont, CA USA
[3] Stanford Univ, Sch Med, Div Epidemiol, Dept Hlth Res & Policy, Stanford, CA 94305 USA
关键词
SEER Program; prostatic neoplasms; lymph node metastasis; Gleason score; ACTIVE SURVEILLANCE; REPRODUCIBILITY; ADENOCARCINOMA; CARCINOMA; IMPACT; GRADE;
D O I
10.1097/PAT.0000000000000097
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Based on revisions of Gleason scoring in 2005, it has been reported that nodal metastases at radical prostatectomy in Gleason 3 + 3 = 6 (GS6) prostate cancer are extremely rare, and that GS6 cancers with nodal metastases are invariably upgraded upon review by academic urological pathologists. We analysed the prevalence and determinants of nodal metastases in a national sample of patients with GS6 cancer. We utilised the SEER database to identify patients diagnosed with GS6 prostate cancer during 2004-2010 who had radical prostatectomy and >= 1 lymph node(s) examined. We calculated the prevalence of nodal metastases and constructed a multivariable logistic regression model to identify factors associated with nodal metastases. Among 21,960 patients, the prevalence of nodal metastases was 0.48%. Older age, preoperative PSA >10 ng/mL, and advanced stage were positively associated with nodal metastases. Lymph node metastases in GS6 cancer are more prevalent in a nationwide population compared to academic centres. Revised guidelines for Gleason scoring have made GS6 cancer a more homogeneously indolent disease, which may be relevant in the era of active surveillance. We submit that lymph node metastases in GS6 cancer be used as a proxy for adherence to the 2005 ISUP consensus on Gleason grading.
引用
收藏
页码:306 / 310
页数:5
相关论文
共 50 条
  • [31] COMPARISON OF BIOCHEMICAL RELAPSE-FREE SURVIVAL BETWEEN PRIMARY GLEASON SCORE 3 AND PRIMARY GLEASON SCORE 4 FOR BIOPSY GLEASON SCORE 7 PROSTATE CANCER
    Burdick, Michael J.
    Reddy, Chandana A.
    Ulchaker, James
    Angermeier, Kenneth
    Altman, Andrew
    Chehade, Nabil
    Mahadevan, Arul
    Kupelian, Patrick A.
    Klein, Eric A.
    Ciezki, Jay P.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 73 (05): : 1439 - 1445
  • [32] Comparison of 3 T mpMRI and pelvic CT examinations for detection of lymph node metastases in patients with prostate cancer
    Valentin, B.
    Arsov, C.
    Ullrich, T.
    Demetrescu, D.
    Morawitz, J.
    Al-Monajjed, R.
    Quentin, M.
    Kirchner, J.
    Esposito, I
    Albers, P.
    Antoch, G.
    Schimmoeller, L.
    EUROPEAN JOURNAL OF RADIOLOGY, 2022, 147
  • [33] Gleason Score 3+5 or 5+3 versus 4+4 Prostate Cancer: The Risk of Death
    Mai Anh Huynh
    Chen, Ming-Hui
    Wu, Jing
    Braccioforte, Michelle H.
    Moran, Brian J.
    D'Amico, Anthony V.
    EUROPEAN UROLOGY, 2016, 69 (06) : 976 - 979
  • [34] Androgen receptor status of lymph node metastases from prostate cancer
    Hobisch, A
    Culig, Z
    Radmayr, C
    Bartsch, G
    Klocker, H
    Hittmair, A
    PROSTATE, 1996, 28 (02) : 129 - 135
  • [35] Prognostic implications of extracapsular extension of lymph node metastases in prostate cancer
    Griebling, TL
    Ozkutlu, D
    See, WA
    Cohen, MB
    MODERN PATHOLOGY, 1997, 10 (08) : 804 - 809
  • [36] A contemporary analysis of disease upstaging of Gleason 3+3 prostate cancer patients after robot-assisted laparoscopic prostatectomy
    Taggart, Ruairidh
    Dutto, Lorenzo
    Leung, Hing Y.
    Salji, Mark
    Ahmad, Imran
    CANCER MEDICINE, 2023, 12 (22): : 20830 - 20837
  • [37] Is pelvic lymph node dissection necessary in patients with biopsy proven Gleason 6 prostate cancer? - analysis of the SEER database
    Daugherty, Michael
    Sedaghatpour, Dillon
    Bratslaysky, Gennady
    Shapiro, Oleg
    CANADIAN JOURNAL OF UROLOGY, 2018, 25 (04) : 9414 - 9420
  • [38] Molecular and Functional Imaging for Detection of Lymph Node Metastases in Prostate Cancer
    Fortuin, Ansje
    de Rooij, Maarten
    Zamecnik, Patrik
    Haberkorn, Uwe
    Barentsz, Jelle
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2013, 14 (07): : 13842 - 13857
  • [39] miR-145-5p: A Potential Biomarker in Predicting Gleason Upgrading of Prostate Biopsy Samples Scored 3+3=6
    Wang, Tao
    Dong, Lei
    Sun, Juanjuan
    Shao, Jialiang
    Zhang, Jian
    Chen, Siteng
    Wang, Chaofu
    Wu, Gangfeng
    Wang, Xiang
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 9095 - 9106
  • [40] Do Adenocarcinomas of the Prostate With Gleason Score (GS) ≤ 6 Have the Potential to Metastasize to Lymph Nodes?
    Ross, Hillary M.
    Kryvenko, Oleksandr N.
    Cowan, Janet E.
    Simko, Jeffry P.
    Wheeler, Thomas M.
    Epstein, Jonathan I.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2012, 36 (09) : 1346 - 1352